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 The aim of this study is to compare two different productions of 
Albanian and Canadian B-complex multivitamin tablets on the Albanian 
pharmaceutical market through various ‘in vitro’ pharmacopeias tests and 
argue about the regulatory legislative framework of drugstore sale of these 
products. Identification, weight uniformity, hardness and disintegration tests 
are carried out for the specific vitamins pyridoxine, niacin and riboflavin in 
these multivitamin B-complex tablets. The quality control tests implemented 
for the different productions of Albanian and Canadian B-complex tablets 
ensues that both of the productions fulfill the limits of pharmacopoeia for the 
presented tests. In the comparison of these products, it is noticed difference 
in technological formulation, packing and price per tablet. The retrospective 
analysis of the legislative framework shows a gap in the marketing and sale 
protection for these multivitamin tablets as genuine pharmaceutical products. 
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Introduction 
 The aim of this study is to make a comparison of two different 
productions of B-complex multivitamin tablets, Canadian and Albanian, 
available in the Albanian Pharmaceutical market. The comparison is 
evaluated through different quality control tests and costs. It also argues 
about the regulatory legislative regulation of drugstore sale of these products. 
The comparison is evaluated through performing the quality control tests. 
Quality control is that part of the GMP that includes the taking of the 
samples, specifications and analysis, organization, documentation and 
release/admission procedures that guarantee that the respective and necessary 
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analysis are performed and that the materials are not admitted/released for 
usage, nor the products are not admitted/released for sale or supply until the 
moment that their quality must be considered as acceptable. Both 
productions of B-complex multivitamin tablets are registered in the Albanian 
Pharmaceutical market by the Registration Authorities and consist of 
common specific vitamins of Riboflavin (B2), Pyridoxine (B6) and Niacin 
(B3). Riboflavin is involved in the energy production for the electron 
transport chain, the citric acid cycle, as well as the catabolism of fatty acids 
(beta oxidation) . Pyridoxine is linked to cardiovascular health by decreasing 
the formation of homo cysteine. Pyridoxine may help balance hormonal 
changes in women and aid the immune system (Kashanian, M.; Mazinani, 
R.; Jalalmanesh, S., 2007). Niacin is the oldest lipid lowering drug. It 
reduces secondary outcomes associated with atherosclerosis, such as low 
density lipoprotein cholesterol (LDL), very low-density lipoprotein 
cholesterol (VLDL-C), and triglycerides (TG), but increases high density 
lipoprotein cholesterol (HDL) (Villines TC, Kim AS, Gore RS, Taylor AJ 
2012).  
 The B-complex vitamin tablets are included in the nutritional 
supplement group and therefore are controlled by the Albanian Drug 
Authorities according to the operative legislation. Today, this legislation 
lacks in the inclusiveness of all multivitamins productions in the 
dietary/nutritional supplements regulations. 
 
Materials and Methods 
 Reagents and chemical agents used in the study for the experimental 
part are two different productions of B komplex multivitamin tablets 
Canadian and Albanian productions. The main apparatus used are analytical 
scale, Varian hardness test apparatus, Varian UV-Vis Spectrophotometer, 
disintegration apparatus Guoming BJ-2. Subject to the quality control test are 
the common specific vitamins of Riboflavin (B2), Pyridoxine (B6) and 
Niacin (B3) that constitute the two different productions of B komplex 
multivitamin tablets.  
 
Calibration Curves 
 For each vitamin (Riboflavin, Pyridoxine and Niacin) contained in 
the B komplex multivitamin tablets, the calibration curves are designed. For 
Riboflavin, mother water solution of 100µg/ml is created by dissolving 
100mg riboflavin in 100ml NaOH 0,1N and 10ml of this solution is diluted 
in 100ml NaOH 0,1N. Therefore the calibration solutions are obtained (5-
20µg/ml). NaOH 0,1N is used as blank.  
 For Pyridoxine the mother solution was obtained from dissolving 10 
mg of pyridoxine in 100ml carbon dioxide-free water. This is 0,1 mg/ml 
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mother solution. The standard solutions are created in the concentrations 0,5-
20µg/ml.  Water was used as blank.  
 200 mg of Niacin are dissolved 500ml in carbon dioxide-free water. 
Mother solution 0,4 mg/ml was obtained. The standard solutions are 8-
40µg/ml. Water was used as blank.  
 For every solution, the absorbance is measured in the maximum 
absorbance wavelength (respective λ max riboflavin=450nm; λ max 
pyridoxine=290.1nm; λ max niacin= 259.9nm). The calibration curves were carried 
out and designed through Cary Varian data software. 
 
Identification 
 Identification of the presence of riboflavin in each production of B 
complex vitamin tablet was performed through spectrophotometric method. 
1 tablet of each production was dissolved in 3ml NaOH and 3ml glacial 
acetic acid, and then diluted in 100ml H2O. The spectrum was obtained in 
the spectral range [200-500nm]. The absorbance ratios were evaluated 
A273/A267, and A444/A264 according to European Pharmacopeia 5.0, in 
the monograph ‘Riboflavin identification’ (pg 2366). 
 Identification of Pyridoxine was performed by dissolving 2.50 g of 
pyridoxine in 50ml in carbon dioxide-free water (solution S). Solution S 
should give typical reaction of chlorides (2.3.1 EuPh 5.0) of deep red color. 
 Identification of Niacin was made by evaluating the ratio A237/A262 
from the niacin spectrum of the solutions of 20µg/ml of each production 
according to the United States Pharmacopoeia National Formulary 
monograph, ‘Niacin identification’ (pg 1080-1081). 
 
Weight Variation 
 20 tablets of each production of B-complex tablets were weighted 
individually. Then the average weight (g) was evaluated as well as standard 
deviation (stdev) and the percentage deviation.  The statistical evaluations 
were performed with Microsoft Office Excel 2007. 
 According to USP limits of weight variation, not more than two of 
the individual weight can deviate from the average weight of not more than 
10% according to The United States Pharmacopeial Convention (2011), that 
discusses about  Uniformity of Dosage Units. 
 
Hardness test 
 Hardness test is a non pharmacopeia test. Oral tablets have a hardness 
of 4-10kg (Bettiol, 2010). 10 tablets of each production of B-complex tablets 
were measured individually. The average hardness and standard deviation 
(stdev) was evaluated through Microsoft Office Excel 2007. 
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Disintegration test 
 3 tablets of each production of B-complex tablets are measured for 
the disintegration test in distilled water (900ml, 37°C, 30 min) in Guoming 
BJ-2 apparatus. One dosage unit was placed in each of the six tubes of the 
basket. According to USP, if one or two dosage units fail to disintegrate, the 
test is repeated on 12 additional dosage units. The requirements of the test 
are met if not less than 16 of the 18 dosage units tested are disintegrated 
according to  Revision Bulletin Official (2008). 
 
Legislative regulation 
 Legislative regulation for nutritional supplements in Albania was 
analyzed through the currently operative directive Law Nr. 9323 date 
25.11.2004 «Drugs and pharmaceutical service», regulation «Registration 




 The calibration curve of each vitamin was obtained according to the 
method described previously. For riboflavin and niacin the correlation 
coefficient was 0,999. The pyridoxine calibration curve was a linear 
regression with good correlation coefficient was 0,991.  
 
Graphic1. The calibration curve of riboflavin 
 
 
Graphic 2. The calibration curve of pyridoxine 
 




Graphic 3. The calibration curve of niacin 
 
Identification 
 The identification of riboflavin through UV-Vis spectrophotometer, 
showed the characteristic spectrum of riboflavin with two peaks, (λmax 1 = 
260nm, λmax 2 =430nm). The absorbance ratios were: A273/A267 = 0,313 and 
A444/A264 =0,368. The ratios were within the limits described by the 
European Pharmacopoeia A273/A267[0,31-0,33]; A444/A264[0,36-0,39]. 
 Identification of pyridoxine through the reaction of the aqueous 
solution of powdered tablets with ferric (III) chloride showed a deep red 
color as described in the (2.3.1 EuPh 5.0).  
 The ratio A237/A262 of niacin of the solutions of 20µg/ml of each 
production (Canadian and Albanian tablet) was evaluated to be 0,37 and 0,68 
respectively,  which fell in the limits range of [0,35-0,39] according to USP. 
 
Weight variation 
 The weight variation results showed that any of the two productions 
of B complex vitamin passed the limit of the percentage of deviation of 10% 
as described in the USP. The results are showed in table 1.  
 
Hardness test 
 The hardness test results in table 1 showed that the Albanian 
production had a lower value of hardness compared to the Canadian tablets. 
The advised value is 4-10 Kpa, otherwise the disintegration test should be 
conducted, since the hardness test is not a pharmacopeia test.  
 
Disintegration test  
 According to USP limit, disintegration time of both productions was 
within the limits of 30min. The results are showed in table1. 
  
Weight variation    




(kpa ± stdev) 
Disintegration 
time (min) 
Albanian B complex 
tablet 0,2543 ± 0,0099 8% 3,66 ± 0,74 15,46 
Canadian B complex 
tablet 1,3632 ± 0,0092 1,80% 25,04 ± 1,73 21,06 
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Table1. The results for weight variation test (along with the maximum 
%deviation value calculated), hardness test and disintegration test. 
 
Legislative regulation 
 The retrospective analysis of legislative regulation in Albania showed 
that there is no strict difference in what is considered dietary/nutritional 
supplement and what is considered food. In this gap created, there are can be 
many dietary supplements (even in high vitamin doses) sold in the Albanian 
market with no control of the drug authorities. 
 
Conclusion 
 The quality control tests implemented for the different productions of 
Albanian and Canadian B-complex tablets ensues that both of the 
productions fulfill the limits of pharmacopoeia for the presented tests 
(identification, weight variation, disintegration). In the comparison of these 
products, it is noticed difference in technological formulation, hardness and 
packaging.  
 The retrospective analysis of the legislative framework shows a gap 
in the marketing and sale protection for these multivitamin tablets as genuine 
pharmaceutical products. There is a thin line of distinction between 
food/health supplement and drugs, particularly in a case where the contents 
and concentration of nutritional value and vitamins are specifically 
mentioned for various commercial reasons, making the categorization highly 
subjective. There is also no judicial unanimity in this regard. There is no 
specific statutory or judicial yardstick available for being decisive on this 
aspect. That leads to the conclusion that the categorization of health and 
nutritional supplements as "food supplement" or "drug" would depend on the 
analysis of the ingredients/composition of the specific supplement as well as 
subjectivity of the authorities. 
 The Health Services should make an expertise to analyze the 
ingredients or components of each drug to know the effect of such drugs on 
the human body. These kind of analysis, can tell us whether we have a 'drug' 
or a 'food'. 
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